



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Suzy Charbit et al.

Application No.: 10/507,485

Filing Date: January 31, 2005

Title: ENANTIOMER (-) OF TENATOPRAZOLE AND THE THERAPEUTIC USE THEREOF

Group Art Unit: 1625

Examiner: Margaret M. Seaman

Confirmation No.: 8571

AMENDMENT/REPLY TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a reply for the above-identified patent application.

- ☐ A Petition for Extension of Time is also enclosed.
- ☐ Terminal Disclaimer(s) and the ☐ \$65.00 (2814) ☐ \$130.00 (1814) fee per Disclaimer due under 37 C.F.R. § 1.20(d) are also enclosed.
- ☒ Also enclosed is/are Declaration of George Sachs Pursuant to 37 CFR 1.132, Exhibit A, Exhibit B, and two articles entitled "Goodman & Gilman's The Pharmacologicla Basis of Therapeutics", and "Harrison's Principles of Internal Medicine".
- ☐ Small entity status is hereby claimed.
- ☐ Applicant(s) requests continued examination under 37 C.F.R. § 1.114 and enclose the ☐ \$395.00 (2801) ☐ \$790.00 (1801) fee due under 37 C.F.R. § 1.17(e).
- ☐ Applicant(s) requests that any previously unentered after final amendments not be entered. Continued examination is requested based on the enclosed documents identified above.
- ☐ Applicant(s) previously submitted _____

on _____
for which continued examination is requested.
- ☐ Applicant(s) requests suspension of action by the Office until at least _____, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.
- ☐ A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (1809/2809) is also enclosed.

- ☒ No additional claim fee is required.
- ☐ An additional claim fee is required, and is calculated as shown below.

AMENDED CLAIMS					
	No. of Claims	Highest No. of Claims Previously Paid For	Extra Claims	Rate	Additional Fee
Total Claims	25	MINUS 30 =	0	x \$50.00 (1202) =	\$ 0.00
Independent Claims	8	MINUS 9 =	0	x \$200.00 (1201) =	\$ 0.00
If Amendment adds multiple dependent claims, add \$360.00 (1203)					
Total Claim Amendment Fee					\$ 0.00
<input type="checkbox"/> Small Entity Status claimed - subtract 50% of Total Claim Amendment Fee					\$ 0.00
TOTAL ADDITIONAL CLAIM FEE DUE FOR THIS AMENDMENT					\$ 0.00

- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to Deposit Account No. 02-4800.
- ☐ Charge _____ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.


Respectfully submitted,

BUCHANAN INGERSOLL PC


P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: November 7, 2005

By



Melissa M. Hayworth
Registration No. 45,774



Patent
Attorney's Docket No. 032013-103

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)	
)	
Avraham COHEN et al.)	Group Art Unit: 1625
)	
Application No.: 10/507,485)	Examiner: Margaret M. Seaman
)	
Filed: September 13, 2004)	Confirmation No.: 8571
)	
For: ENANTIOMER (-) OF)	
TENATOPRAZOLE AND THE)	
THERAPEUTIC USES THEREOF)	

RESPONSE UNDER 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In complete response to the Office Action dated August 15, 2005, please amend the above-identified patent application as follows.

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of the Response.

Remarks begin on page 7 of this Response.

Attached is a declaration of George Sachs, M.D., D.Sc., pursuant to 35 U.S.C. § 1.132.